Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 15/20 | 0.58 |
| ▸ | ROCK1 | Q13464 | 10/20 | 0.58 |
| ▸ | ARHGDIA | P52565 | 4/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.48 |
| ▸ | CLK1 | P49759 | 2/20 | 0.48 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.48 |
| ▸ | CLK2 | P49760 | 1/20 | 0.48 |
| ▸ | CLK3 | P49761 | 1/20 | 0.48 |
| ▸ | GSK3B | P49841 | 1/20 | 0.48 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.48 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.48 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.48 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.48 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.48 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | CCR2 | P41597 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL747065 | 1.00 | ROCK2 (0.58) | ROCK2ROCK1ARHGDIACYP3A4CHRNA7 | |
| SCHEMBL5413381 | 0.91 | ROCK2 (0.67) | ROCK2ROCK1ARHGDIACYP3A4CCR2 | |
| Fumaric Acid SCHEMBL989059 | 0.91 | ROCK2 (0.52) | ROCK2ROCK1ARHGDIACYP3A4CLK1 | |
| Fumaric Acid SCHEMBL989060 | 0.91 | ROCK2 (0.52) | ROCK2ROCK1ARHGDIACYP3A4CLK1 | |
| SCHEMBL746411 | 0.89 | ROCK2 (0.52) | ROCK2ROCK1ARHGDIACYP3A4CHRNA7 | |
| SCHEMBL746412 | 0.89 | ROCK2 (0.52) | ROCK2ROCK1ARHGDIACYP3A4CHRNA7 | |
| SCHEMBL910665 | 0.87 | ROCK2 (0.62) | ROCK2ROCK1ARHGDIACYP3A4CCR2 | |
| SCHEMBL748442 | 0.82 | NPC1 (0.44) | ROCK2ROCK1ARHGDIACHRNA7GSK3B | |
| SCHEMBL748443 | 0.82 | NPC1 (0.44) | ROCK2ROCK1ARHGDIACHRNA7GSK3B | |
| SCHEMBL5407772 | 0.81 | ROCK2 (0.64) | ROCK2ROCK1ARHGDIACYP3A4CCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2431368-A1 | CNS active fused bicycloheterocycle substituted azabicyclic alkane derivatives | Abbott Laboratories (US) | 2012-03-21 | — | — | EP | claimed |
| EP-2018380-B1 | Cns active fused bicycloheterocycle substituted azabicyclic alkane derivatives | ABBOTT LAB (US) | 2011-10-19 | — | — | EP | claimed |
| US-20100305089-A1 | Fused Bicycloheterocycle Substituted Azabicyclic Alkane Derivatives | ABBOTT LABORATORIES (US) | 2010-12-02 | — | — | US | claimed |
| US-20080045539-A1 | FUSED BICYCLOHETEROCYCLE SUBSTITUTED AZABICYCLIC ALKANE DERIVATIVES | ABBVIE INC. | 2008-02-21 | — | — | US | claimed |
| US-8940762-B2 | Methods for treating pain | ABBVIE INC. (US) | 2015-01-27 | — | — | US | disclosed |
| EP-2431368-A1 | CNS active fused bicycloheterocycle substituted azabicyclic alkane derivatives | Abbott Laboratories (US) | 2012-03-21 | — | — | EP | disclosed |
| EP-2018380-B1 | Cns active fused bicycloheterocycle substituted azabicyclic alkane derivatives | ABBOTT LAB (US) | 2011-10-19 | — | — | EP | disclosed |
| US-20110178121-A1 | Methods for Treating Pain | ABBOTT LABORATORIES (US) | 2011-07-21 | — | — | US | disclosed |
| US-7872017-B2 | Fused bicycloheterocycle substituted azabicyclic alkane derivatives | ABBOTT LABORATORIES (US) | 2011-01-18 | — | — | US | disclosed |
| US-20100305089-A1 | Fused Bicycloheterocycle Substituted Azabicyclic Alkane Derivatives | ABBOTT LABORATORIES (US) | 2010-12-02 | — | — | US | disclosed |
| US-20080045539-A1 | FUSED BICYCLOHETEROCYCLE SUBSTITUTED AZABICYCLIC ALKANE DERIVATIVES | ABBVIE INC. | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045539-A1 | FUSED BICYCLOHETEROCYCLE SUBSTITUTED AZABICYCLIC ALKANE DERIVATIVES | MALT1, BMP2, ALKBH2 | ROCK2 3093/4885ROCK1 4137/4885ARHGDIA 3491/4885 |
| US-20100305089-A1 | Fused Bicycloheterocycle Substituted Azabicyclic Alkane Derivatives | MALT1, BMP2, ALKBH2 | ROCK2 3093/4885ROCK1 4137/4885ARHGDIA 3491/4885 |
| US-20110178121-A1 | Methods for Treating Pain | CHRNA7, CHRNA3, CHRNA5 | ROCK2 1434/4885ROCK1 1446/4885ARHGDIA 1736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.